newsA first-of-its-kind trial testing a novel psilocin-based drug for major…
28 June 2023 | By Catherine Eckford (European Pharmaceutical Review)
A first-of-its-kind trial testing a novel psilocin-based drug for major depressive disorder has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA).